NCT00039962已完成3 期
Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin
SciClone Pharmaceuticals58 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2002年5月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 500
- 试验地点
- 58
研究概览
简要总结
Chronic hepatitis C infection is one of the leading causes of chronic liver disease in the United States. Approximately one-third of patients with hepatitis C infection develop cirrhosis of the liver, which can lead to liver failure or liver cancer. The current treatment for hepatitis C infection in previously untreated patients is successful in only about half of patients. There is no established therapy for non-responders.
This is a randomized, double-blinded, multicenter trial to determine the effectiveness of thymosin alpha 1 (thymalfasin) 1.6 mg twice weekly plus PEGinterferon alfa-2a 180 ug/wk compared to placebo plus PEGinterferon alfa-2a in adults with chronic hepatitis C with early cirrhosis or progression to cirrhosis who are non-responders to previous treatment with interferon or interferon plus ribavirin. The definition of non-response requires a positive HCV RNA test at the end of a course of at least 12 weeks of therapy. Patients will receive treatment for 12 months, and will be followed-up for a further 6 months after the end of therapy
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent.
- •Age over 18 years old.
- •Presence of HCV RNA measured by qualitative PCR.
- •Nonresponder to a previous course of therapy with either IFN alone or IFN plus ribavirin. The patient must have been treated for at least 3 months (12 weeks).
- •Washout period of at least 6 months from previous therapy with IFN alone or IFN plus Ribavirin.
- •Liver biopsy consistent with cirrhosis or progression to cirrhosis (METAVIR fibrosis score 3 to 4) due to chronic hepatitis C within the last 12 months before treatment starts, and at least 6 months after the end of the prior failed therapy.
- •Cirrhosis classified as Child-Pugh "A" (no more than 6 points).
- •Compensated liver disease with prothrombin time prolonged less than 3 seconds over control, total bilirubin < 2 mg/dl, and no history of hepatic encephalopathy, bleeding varices or a history of detection of stigmata of recent bleeding on existing varices or ascites.
- •Ultrasound, CT scan, or MRI of the liver within 3 months of entry negative for HCC.
- •Hematocrit > 30%, platelet count > 75,000, WBC > 2,500, and absolute neutrophil cell count > 1,
- •Adequate renal function as demonstrated by serum creatinine level < 2.0 mg/dl.
- •Normal TSH or adequately controlled thyroid function.
- •If the patient is a woman, she is using a definitive method of birth control in consultation with her physician, or is surgically sterile, or post-menopausal.
排除标准
- •Use of systemic corticosteroids within 6 months of entry.
- •Evidence of drug-induced liver injury.
- •Current use of any drug known to have or suspected of having therapeutic activity in hepatitis C, or any immunosuppressive drug (including corticosteroids).
- •Evidence of any other liver disease including hepatitis B, hepatitis delta, alcoholic liver disease, primary biliary cirrhosis, sclerosing cholangitis, autoimmune hepatitis, hemochromatosis, alpha 1-antitrypsin deficiency, or Wilson's disease.
- •Alpha-fetoprotein > 200 ng/mL.
- •Child-Pugh "B" or "C" cirrhosis (score of 7 or more points), either currently or at any occasion in the past.
- •Decompensated liver disease based on a history of hepatic encephalopathy, bleeding varices or a history of detection of stigmata of recent bleeding on existing varices, or ascites.
- •HIV infection diagnosed by HIV seropositivity and confirmed by Western blot.
- •Concomitant or prior history of malignancy other than curatively treated skin cancer or surgically cured in situ carcinoma of the cervix.
- •Active infectious process other than HCV that is not of a self-limited nature.
- •Rheumatoid arthritis or other autoimmune disease (serum ANA > 1:160.).
- •Pregnancy as documented by a urine pregnancy test.
- •Alcohol or intravenous drug abuse within the previous 1 year.
- •Chronic use of methadone.
- •Patients who are poor medical risk or who have any non-malignant systemic disease that, in the opinion of the investigator, would make it unlikely that the patient could complete the protocol.
- •Patients with a history of severe depression that required either hospitalization or electroshock therapy; or depression associated with suicide attempt.
- •Patients with significant pre-existing cardiac or pulmonary disease.
- •Recipients of transplants.
- •Patients with uncontrolled seizure disorder.
- •Any indication that the patient would not comply with the conditions of the study protocol.
- •Previous treatment with thymosin alpha
- •Patients with known hypersensitivity to IFN a.
- •Simultaneous participation in another investigational drug study, or participation in any clinical trial involving investigational drugs within 3 months of study entry.
- •Family history of intracerebral hemorrhage.
研究者
研究点 (58)
Loading locations...
相似试验
已完成
3 期
Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus RibavirinHepatitis C, ChronicHepatitis CNCT00040027SciClone Pharmaceuticals500
已完成
2 期
Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)Hepatitis CThalassemiaNCT00502788Carelon Research21
撤回
4 期
Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC PolymorphismHepatitis CNCT01415141University of Vermont
已完成
3 期
Combination Drug Therapy for Patients With Hepatitis CChronic Hepatitis CFibrosisHemolytic AnemiaNCT00001729National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)120
已完成
4 期
Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral TherapyHepatitis CNCT01045278Region Skane277